BioSpace News Archive

Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion recommending marketing authorization of Mirataz®

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has expanded its Board of Directors with the appointment of Todd C. Peterson, Ph.D.

Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today a corporate restructuring to extend the company’s cash runway without impacting or delaying the data timelines of its clinical programs.

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced its results for the third quarter, ended September 30, 2019, will be released on Wednesday, October 30, 2019 after market close

OCHIN is a national nonprofit organization that helps community health centers provide the highest quality care through advanced technology.

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors.

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance exchange, announced today that the company plans to release third quarter 2019 financial results on October 24, 2019.

Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.

TALTZ met the primary endpoint of the IXORA-R study, with 41.3 percent of patients taking TALTZ achieving complete skin clearance as measured by PASI 100 at Week 12 versus 24.9 percent of patients taking TREMFYA